Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms

作者：Prithviraj Bose, Zhijian Xiao, Hans Carl Hasselbalch, Josef T. Prchal, Minghui Duan, Abdulraheem Yacoub, Raajit K. Rampal, Jean‐Jacques Kiladjian, Gabriela Hobbs, Tsewang Tashi, Kazuya Shimoda, Keita Kirito, Harinder Gill, Hsin‐An Hou, Sung Eun Lee, Jian Huang, Bing Li, Albert Qin, Lennex Hsueh‐Lin Yu, John Mascarenhas, Ruben A. Mesa · 发表于：Current Hematologic Malignancy Reports · 年份：2025 · DOI：10.1007/s11899-025-00752-3 · 被引用次数：4 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Acute Myeloid Leukemia Research、Eosinophilic Disorders and Syndromes

PURPOSE OF REVIEW: This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data. RECENT FINDINGS: Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more...